ZNTLZentalis Pharmaceuticals, Inc.

Nasdaq zentalis.com


$ 12.52 $ 0.09 (0.72 %)    

Thursday, 09-May-2024 15:59:55 EDT
QQQ $ 441.33 $ 0.96 (0.22 %)
DIA $ 394.43 $ 3.52 (0.9 %)
SPY $ 520.56 $ 3.37 (0.65 %)
TLT $ 90.69 $ 0.50 (0.55 %)
GLD $ 216.93 $ 3.37 (1.58 %)
$ 12.52
$ 12.65
$ 0.00 x 0
$ 0.00 x 0
$ 12.41 - $ 12.79
$ 9.56 - $ 31.46
1,022,881
na
884.92M
$ 1.22
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-06-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-01-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-25-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-15-2020 03-31-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-zentalis-pharma-lowers-price-target-to-40

HC Wainwright & Co. analyst Andrew Fein maintains Zentalis Pharma (NASDAQ:ZNTL) with a Buy and lowers the price target f...

 stifel-maintains-buy-on-zentalis-pharma-lowers-price-target-to-32

Stifel analyst Bradley Canino maintains Zentalis Pharma (NASDAQ:ZNTL) with a Buy and lowers the price target from $36 to $32.

 zentalis-pharmaceuticals-to-highlight-preclinical-data-demonstrating-that-wee1-inhibitor-azenosertib-exerts-synergistic-anti-tumor-activity-with-krasg12c-inhibitors-at-aacr-annual-meeting-2024

Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically...

 hc-wainwright--co-reiterates-buy-on-zentalis-pharma-maintains-46-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Zentalis Pharma (NASDAQ:ZNTL) with a Buy and maintains $46 price target.

 wedbush-maintains-neutral-on-zentalis-pharma-raises-price-target-to-15

Wedbush analyst Robert Driscoll maintains Zentalis Pharma (NASDAQ:ZNTL) with a Neutral and raises the price target from $12 ...

 zentalis-pharma-fy-eps-447-up-from-448-yoy-cash-balance-of-483m-with-projected-cash-runway-into-2026

Zentalis Pharma (NASDAQ:ZNTL) reported quarterly losses of $(4.47) per share. This is a 0.22 percent increase over losses of $(...

Core News & Articles

Under the terms of the deal, Zentalis will receive an up-front payment of $35 million in cash and Immunome common stock. Zental...

 wedbush-downgrades-zentalis-pharma-to-neutral-lowers-price-target-to-12

Wedbush analyst Robert Driscoll downgrades Zentalis Pharma (NASDAQ:ZNTL) from Outperform to Neutral and lowers the price tar...

 stifel-maintains-buy-on-zentalis-pharma-lowers-price-target-to-36

Stifel analyst Bradley Canino maintains Zentalis Pharma (NASDAQ:ZNTL) with a Buy and lowers the price target from $44 to $36.

 morgan-stanley-maintains-overweight-on-zentalis-pharma-lowers-price-target-to-38

Morgan Stanley analyst Matthew Harrison maintains Zentalis Pharma (NASDAQ:ZNTL) with a Overweight and lowers the price targe...

 hc-wainwright--co-maintains-buy-on-zentalis-pharma-lowers-price-target-to-46

HC Wainwright & Co. analyst Andrew Fein maintains Zentalis Pharma (NASDAQ:ZNTL) with a Buy and lowers the price target f...

 treehouse-foods-echostar-hilton-grand-vacations-echostar-and-other-big-stocks-moving-lower-on-monday

U.S. stocks traded higher, with the Dow Jones gaining around 25 points on Monday. Here are some big stocks recording losses in ...

 zentalis-pharma-q3-eps-079-vs-096-prior-year

Zentalis Pharma (NASDAQ:ZNTL) reported quarterly losses of $(0.79) per share. This is a 17.71 percent increase over losses of $...

 zentalis-pharmaceuticals-13g-filing-shows-eventide-asset-management-llc-holds-1107-stake-in-co

- SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION